A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS

被引：0
|
作者：
Vigil, E. [1 ]
Griffiths, A. [1 ]
Thompson, E. [1 ]
Brady, E. [1 ]
Dickey, M. [1 ]
Ford, A. [1 ]
Wang, S. [1 ]
Wetzler, M. [1 ]
机构：
[1] Roswell Park Canc Inst, Buffalo, NY 14263 USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0082
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    [J]. LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [2] A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Griffiths, Elizabeth A.
    Brady, William
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Sperrazza, Jill
    Wang, Eunice S.
    Wetzler, Meir
    [J]. BLOOD, 2014, 124 (21)
  • [3] Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?
    Bertoli, Sarah
    Gadaud, Noemie
    Tavitian, Suzanne
    Sarry, Audrey
    Berard, Emilie
    Huguet, Francoise
    Recher, Christian
    [J]. BLOOD, 2016, 128 (22)
  • [4] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Foster, Matthew
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Scibilia, Richard
    Blanchard, Laura
    Frank, Cassiopeia
    Gallagher, Sean
    Matson, Melissa
    Pepin, Katherine
    Vaught, Lori
    Vogler, Nancy
    Gojo, Ivana
    Luznik, Leo
    Serody, Jonathan S.
    [J]. BLOOD, 2017, 130
  • [5] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    [J]. BLOOD, 2010, 116 (21) : 464 - 465
  • [6] Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
    Ottmann, Oliver G.
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Schlenk, Richard F.
    Luebbert, Michael
    Bug, Gesine
    Krug, Utz
    Bochtler, Tilmann
    Voss, Florian
    Taube, Tillmann
    Liu, Dan
    Garin-Chesa, Pilar
    Doehner, Hartmut
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (06) : 1017 - 1020
  • [7] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Kuchroo, Manik Razdan
    Redd, Robert A.
    Garcia, Jacqueline S.
    Keng, Michael
    Hobbs, Gabriela S.
    Rosenblatt, Jacalyn
    Luskin, Marlise R.
    Narayan, Rupa
    Amrein, Philip C.
    McMasters, Malgorzata
    Wadleigh, Martha
    Hock, Hanno
    Stone, Richard
    Neuberg, Donna S.
    Avigan, David
    Ballen, Karen K.
    Fathi, Amir T.
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    [J]. BLOOD, 2023, 142
  • [8] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Schnetzke, Ulf
    Fix, Peter
    Spies-Weisshart, Baerbel
    Schrenk, Karin
    Glaser, Anita
    Fricke, Hans-Joerg
    La Rosee, Paul
    Hochhaus, Andreas
    Scholl, Sebastian
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (08) : 1391 - 1397
  • [9] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Ulf Schnetzke
    Peter Fix
    Baerbel Spies-Weisshart
    Karin Schrenk
    Anita Glaser
    Hans-Joerg Fricke
    Paul La Rosée
    Andreas Hochhaus
    Sebastian Scholl
    [J]. Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1391 - 1397
  • [10] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    [J]. BLOOD, 2016, 128 (22)
12345